Our portfolio

Advesya is a pioneering biopharma company for difficult-to-treat cancers.

The creation of Advesya was based on decades of research carried out by experienced scientists from the French Blood Institute (EFS) who spun off the activity in 2021.

Advesya aims to rapidly bring new innovations to the cancer therapy sector, starting with aiding refractory Acute Myeloid Leukemia patients, followed by other hematological malignancies.

NMD Pharma A/S, is a private biotechnology company leading in the development of novel first-in-class therapies for severe neuromuscular disorders. The Company was incorporated as a spin-off from Aarhus University, Denmark in 2015 and was founded on more than 15 years of muscle physiology research with a focus on regulation of skeletal muscle excitability under physical activity.

EyeBio is a newly launched global company developing the next generation of eye disease therapies

Founded by two pioneers in ophthalmology drug development to build and advance diversified pipeline of ocular therapies.

Jeito selects EyeBio as its 8th investment and continues to build a strong & diversified portfolio of companies with groundbreaking therapies in areas of high unmet need.

On the 29th of May 2024, Merck & Co (NYSE: MRK) announced its acquisition of EyeBio, which was exited in July 2024, for a total consideration of up to $3 billion.

Jeito Capital chooses Precirix, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology as its ninth investment.

The financing will allow Precirix to advance its pipeline of precision radiopharmaceuticals.

CDR-Life is a Swiss biotechnology company at the forefront of a new class of highly tumor-specific immuno-oncology therapeutics.

CDR-Life leverages the unique expertise and track record of its founders, who together have developed new approved drugs and entered into major biotechnology agreements.

Jeito chooses CDR-Life as its 10th investment and continues to build a strong and diversified portfolio of companies with breakthrough therapies in areas of unmet needs.

Human Immunology Biosciences (HI-Bio) is a San Francisco-based Phase II clinical-stage Biopharma company, with European development activities.

HI-Bio develops targeted therapies for patients suffering from severe immune-mediated diseases (IMD). It has several late-stage clinical programmes and a strong translational platform, enabling it to address many diseases with unmet medical needs.

On the 22nd of May 2024, Biogen Inc. (Nasdaq: BIIB) announced its acquisition of HI-Bio, which was exited in July 2024, for a total consideration of up to $1.8 billion.

CatalYm is a Phase II clinical-stage Biopharma company developing novel immunotherapies to fight cancer. It is based in Munich.

Its lead drug candidate, Visugromab, is a monoclonal antibody engineered to neutralize the tumor-produced Growth Differentiation Factor-15 (GDF-15), an inhibitor of immune cell infiltration into the tumor tissue.

Noema Pharma is a clinical-stage biotechnology company targeting debilitating central nervous system (CNS) disorders characterized by imbalanced neuronal networks.

The Company has a well differentiated pipeline with four mid clinical-stage therapeutic product candidates in-licensed from Roche.

Corteria Pharmaceuticals is a late preclinical stage biopharma company, developing first-in-class therapies with promising novel approaches for unaddressed heart failure subpopulations, addressing high unmet medical needs. It is based in France.

The company’s pipeline includes three therapies – including two programmes in-licensed from Sanofi – aimed at treating worsening heart failure, right heart failure and acute heart failure with hyponatremia. The Biopharma has the potential for wider exploitation in chronic cardiometabolic diseases.

Aviceda is a private, clinical stage biotechnology company located in Cambridge, MA, with a proprietary High Affinity Ligands of Siglecs (HALOS™) nanotechnology platform and a clinical-stage ophthalmic candidate, AVD-104, for the treatment of geographic atrophy secondary to age-related macular degeneration.

AVD-104 is an intravitreal glycan-coated nanoparticle with a dual mechanism of action that modulates critical inflammatory cellular and complement pathways through 1) direct deactivation of inflammatory microglia/macrophages’ phagocytic activity and repolarization of these activated microglia/macrophages to their healing state and 2) inhibition of complement cascade amplification.

Along with AVD-104, Aviceda has a broad pipeline of products in development in ophthalmology and multiple other therapeutic areas, including immunology, fibrosis, oncology, and neurology.

XyloCor Therapeutics, Inc. is a private, clinical‑stage biopharmaceutical company developing potential best‑in‑class gene therapies to transform outcomes for patients with cardiovascular disease. The Company’s lead product candidate, XC001, is in clinical development to investigate use for patients with ischemic heart disease for whom there are no treatment options. XyloCor has a second preclinical investigational product, XC002, in discovery stage, being developed for the treatment of patients with cardiac tissue damage from heart attacks. The company, which was co‑founded by Ronald Crystal, M.D., and Todd Rosengart, M.D., has an exclusive license from Cornell University.

Headquartered in Seattle and Singapore, Callio Therapeutics is focused on realizing the promise of multi-payload antibody-drug conjugates to transform cancer patient outcomes. The company is developing next-generation, multi-payload antibody-drug conjugates (ADCs) that feature differentiated payload and linker technologies that enable targeted delivery of multi agents to tumor cells to maximize therapeutic benefit. Callio Therapeutics’ lead program is a HER2-targeted dual-payload ADC. Callio Therapeutics was created by Frazier Life Sciences, a longstanding investment firm focused on innovative therapeutics, based on ADC technology and programs exclusively in-licensed from Hummingbird Bioscience.

Augustine Therapeutics is a biotechnology company focused on the treatment of neuromuscular, cardio-metabolic and neurodegenerative diseases through its next-generation approach to selectively inhibit HDAC6. Augustine’s HDAC6 inhibitors has been purposefully designed to selectively inhibit HDAC6 while preserving its beneficial non-catalytic functions.
Augustine’s lead program, AGT-100216, is the first selective HDAC6 inhibitor for long-term treatment of Charcot-Marie-Tooth (CMT) disease. With its novel non-hydroxamate, non-hydrazide producing chemotype, Augustine’s HDAC6 approach is selective, avoids the limitations of other chemotypes, and built for chronic diseases. With this novel approach, the Company will also be targeting diseases beyond CMT, including cardio-metabolic and neurodegenerative diseases. Augustine Therapeutics was founded on the ground-breaking research of Prof. Ludo Van Den Bosch from the VIB-KU Leuven in Belgium.